were 21.6 AE 15.5 and 7.0 AE 5.6, respectively. Rates of death at 30 days and 1 year were 3.4% and 10.6%, respectively. At 30 days, the incidence of all stroke, major vascular complications, life-threatening bleeding, and acute kidney injury (stage 2 or 3) were 3.0%, 5.2%, 7.6% and 4.2%, respectively. Paravalvular regurgitation moderate or greater occurred 9.5%. Device success rate and combined safety endpoint at 30 days were 86.2% and 81.0%, respectively. In a multivariate model, female, chronic kidney disease, diabetes mellitus, pulmonary disease, peripheral vascular disease, paravalvular regurgitation mild or greater, and STS score were significantly associated with reduced survival.
CONCLUSIONS Among those with reduced baseline GFR, TAVR results in an improvement in GFR in a substantial portion of patients. Improvement in GFR following TAVR is independently associated with a reduction in all-cause 1-year mortality in patients with severely symptomatic AS who are at high surgical risk or are inoperable. 
